ClinicalTrials.gg
TerminatedNCT03593213Updated Apr 11, 2022Results posted

Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia

A Phase 3 interventional study of Cariprazine and Placebo in Schizophrenia, sponsored by AbbVie. Terminated at 97 sites in 11 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2022-04-11.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Why this study was terminated
FDA Released Allergan from this post marketing requirement

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
587
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.

Enrollment
5th of 23
587 · median 129
Started
2018
the only one that year
Phase 3
8 of 23
1 open now
Registered
15th of 23
by date
Lead sponsor
2 of 23
AbbVie

Among the 23 studies testing cariprazine in Schizophrenia, this one is the 5th largest by enrollment, is the only one that started in 2018, is one of 8 in phase 3, and was the 15th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cariprazine

cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cariprazine in Schizophrenia, or all of them as a file.
02

Study summary

  1. To evaluate the efficacy and safety of cariprazine at a target dose of 4.5 milligram per day (mg/d) compared with placebo in prevention of relapse in patients with schizophrenia
  2. To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/d compared with placebo in prevention of relapse in patients with schizophrenia who were initially stabilized on a target dose of 4.5 mg/d
03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of schizophrenia for a minimum of 1 year before Visit 1 (Screening).
  • Ability to follow study instructions, complete study assessment tools with minimal assistance and no alteration to the assessment tools, and likely to complete all required visits.
  • Participant meets , Fifth Edition (DSM-5) criteria for schizophrenia as determined by Structured Clinical Interview for DSM-5 (SCID-5).
  • Positive and Negative Syndrome Scale (PANSS) total score >= 70 and \<= 120 at Visit 1 and Visit 2 (Day 1).
  • Rating of at least 4 (moderate) on at least 2 of the following 4 PANSS positive symptoms; P1: delusions; P2: conceptual disorganization; P3: hallucinatory behaviour; P6: suspiciousness/persecution at Visit 1 and Visit 2.

Exclusion criteria

Exclusion Criteria:

  • Currently meeting criteria for any of the following:
  • Schizoaffective disorder, schizophreniform disorder, and other psychotic disorders
  • Bipolar I and II disorder
  • Autism spectrum disorder, intellectual development disorder, delirium, major/minor neurocognitive disorder
  • History of meeting DSM-5 criteria for substance-related disorders (excluding caffeine-related and tobacco-related disorders) within the prior 3 months before Visit 1.
  • Prior participation in any clinical trials involving experimental or drugs within 6 months before Visit 1 or planned during the study.
  • Female Participants who are pregnant, planning to become pregnant during the course of the study, or are currently lactating.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
587 participants (actual)

Study arms

  • Experimental
    Cariprazine 4.5 mg/day (Open-label Treatment Period)

    Cariprazine 1.5 mg capsules orally once daily at Week 1, titrated to 3.0 mg capsules orally once daily at Week 2 and then titrated to 4.5 mg orally once daily from Week 3 through Week 18 in the Open-label Treatment Period.

    Drug: Cariprazine

  • Placebo comparator
    Placebo (Double-blind Treatment Period)

    Cariprazine placebo-matching capsules orally once daily from Week 19 through Week 44 in Double-blind Treatment Period.

    Drug: Placebo

  • Experimental
    Cariprazine 3.0 mg/day (Double-blind Treatment Period)

    Cariprazine 3.0 mg capsules orally once daily from Week 19 through Week 44 in Double-blind Treatment Period.

    Drug: Cariprazine

  • Experimental
    Cariprazine 4.5 mg/day (Double-blind Treatment Period)

    Cariprazine 4.5 mg capsules orally once daily from Week 19 through Week 44 in Double-blind Treatment Period.

    Drug: Cariprazine

Interventions

  • Cariprazine capsules, oral administration, once daily.

  • DrugPlacebo

    Matching placebo capsules, oral administration, once daily.

06

What researchers measure

Primary outcomes

  1. Time to First Relapse During Double-blind Treatment Period

    Time to Relapse is the number of days from randomization to first relapse. Relapse is defined as any 1 of the following: * Increase in Positive and Negative Syndrome Scale(PANSS) by ≥30% for participants who had total score of ≥50 at randomization or ≥10-point increased score with total score \<50 at randomization \[PANSS=30 questions where 1=absence of symptoms to 7=extremely severe symptom;total score=30 to 210;higher score more severe symptoms\] * Increase in Clinical Global Impression-Severity (CGI-S) score by 2 or more points \[1=normal to 7=among most extremely ill\] * Score of \>4 on 1 or more of 7 PANSS items:P1-delusions,P2-conceptual disorganization,P3-hallucinatory behavior,P6-suspiciousness,P7-hostility,G8-uncooperativeness,G14-poor impulse control * Deliberate self-injury * Initiation of treatment with mood stabilizer,antidepressant,antipsychotics or benzodiazepine that exceeds specified allowance * Psychiatric hospitalization * Exacerbation of psychiatric illness

    Time frame: Randomization (Week 18) to End of Treatment (Week 44)

07

Results

Posted Mar 8, 2022

Participant flow

Open-label Treatment Period (18 Weeks)
Participant flow — Open-label Treatment Period (18 Weeks)
MilestoneCariprazine 4.5 mg/Day (Open-label Treatment Period)Placebo (Double-blind Treatment Period)Cariprazine 3.0 mg/Day (Double-blind Treatment Period)Cariprazine 4.5 mg/Day (Double-blind Treatment Period)
Started587000
Completed162000
Not completed425000
Withdrew: Adverse event39000
Withdrew: Lack of efficacy14000
Withdrew: Withdrawal by subject85000
Withdrew: Lost to follow-up51000
Withdrew: Death1000
Withdrew: Protocol deviation5000
Withdrew: Non-compliance with study drug23000
Withdrew: Study terminated by the sponsor90000
Withdrew: Reason not specified13000
Withdrew: Failure to meet randomization criteria104000
Double-blind Treatment Period (26 Weeks)
Participant flow — Double-blind Treatment Period (26 Weeks)
MilestoneCariprazine 4.5 mg/Day (Open-label Treatment Period)Placebo (Double-blind Treatment Period)Cariprazine 3.0 mg/Day (Double-blind Treatment Period)Cariprazine 4.5 mg/Day (Double-blind Treatment Period)
Started0544956
Safety population0534954
Completed0141621
Not completed0403335
Withdrew: Number of participants with relapse event01598
Withdrew: Adverse event0204
Withdrew: Withdrawal by subject0423
Withdrew: Lost to follow-up0541
Withdrew: Pregnancy0001
Withdrew: Protocol deviation0325
Withdrew: Non-compliance with study drug0120
Withdrew: Study terminated by sponsor091113
Withdrew: Reason not specified0130

Outcome measures

PrimaryTime to First Relapse During Double-blind Treatment Period

Time to Relapse is the number of days from randomization to first relapse. Relapse is defined as any 1 of the following: * Increase in Positive and Negative Syndrome Scale(PANSS) by ≥30% for participants who had total score of ≥50 at randomization or ≥10-point increased score with total score \<50 at randomization \[PANSS=30 questions where 1=absence of symptoms to 7=extremely severe symptom;total score=30 to 210;higher score more severe symptoms\] * Increase in Clinical Global Impression-Severity (CGI-S) score by 2 or more points \[1=normal to 7=among most extremely ill\] * Score of \>4 on 1 or more of 7 PANSS items:P1-delusions,P2-conceptual disorganization,P3-hallucinatory behavior,P6-suspiciousness,P7-hostility,G8-uncooperativeness,G14-poor impulse control * Deliberate self-injury * Initiation of treatment with mood stabilizer,antidepressant,antipsychotics or benzodiazepine that exceeds specified allowance * Psychiatric hospitalization * Exacerbation of psychiatric illness

Time frame:
Randomization (Week 18) to End of Treatment (Week 44)
Reported as:
Median · days
Time to First Relapse During Double-blind Treatment Period
daysPlacebo (Double-blind Treatment Period)Cariprazine 3.0 mg/Day (Double-blind Treatment Period)Cariprazine 4.5 mg/Day (Double-blind Treatment Period)
Time to First Relapse During Double-blind Treatment PeriodNA (183.0 to NA)NA (184.0 to NA)NA (NA to NA)
Statistical analysis
  • Placebo (Double-blind Treatment Period) vs Cariprazine 3.0 mg/Day (Double-blind Treatment Period) · Log Rank · p = =0.1576 (The significance level was 0.05 using the log rank test.) · Hazard ratio (hr): 0.56 · 95% CI 0.25 to 1.29Hazard ratio (cariprazine 3.0 or 4.5 mg/day vs. placebo) was based on Cox proportional hazards regression model, with treatment group as an explanatory variable.
  • Placebo (Double-blind Treatment Period) vs Cariprazine 4.5 mg/Day (Double-blind Treatment Period) · Log Rank · p = =0.2066 (The significance level was 0.05 using the log rank test.) · Hazard ratio (hr): 0.61 · 95% CI 0.26 to 1.45Hazard ratio (cariprazine 3.0 or 4.5 mg/day vs. placebo) was based on Cox proportional hazards regression model, with treatment group as an explanatory variable.

Adverse events

Collected over First dose to last dose + 30 days in the Open-label Treatment Period (Up to 23 weeks); First dose to last dose + 30 days in the Double-blind Treatment Period (Up to 35 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cariprazine 4.5 mg/Day (Open-label Treatment Period)1/587 (0.2%)20/587 (3.4%)83/587 (14.1%)
Cariprazine 4.5 mg/Day (Open-label Safety Follow-up)0/273 (0%)7/273 (2.6%)0/273 (0%)
Placebo (Double-blind Treatment Period)0/54 (0%)5/53 (9.4%)5/53 (9.4%)
Cariprazine 3.0 mg/Day (Double-blind Treatment Period)0/49 (0%)0/49 (0%)9/49 (18.4%)
Cariprazine 4.5 mg/Day (Double-blind Treatment Period)0/56 (0%)1/54 (1.9%)3/54 (5.6%)
Placebo (Double-blind Safety Follow-up)0/54 (0%)0/53 (0%)0/53 (0%)
Cariprazine 3.0 mg/Day (Double-blind Safety Follow-up)0/49 (0%)0/49 (0%)1/49 (2%)
Cariprazine 4.5 mg/Day (Double-blind Safety Follow-up)0/56 (0%)2/54 (3.7%)0/54 (0%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventCariprazine 4.5 mg/Day (Open-label Treatment Period)Cariprazine 4.5 mg/Day (Open-label Safety Follow-up)Placebo (Double-blind Treatment Period)Cariprazine 3.0 mg/Day (Double-blind Treatment Period)Cariprazine 4.5 mg/Day (Double-blind Treatment Period)Placebo (Double-blind Safety Follow-up)Cariprazine 3.0 mg/Day (Double-blind Safety Follow-up)Cariprazine 4.5 mg/Day (Double-blind Safety Follow-up)
SchizophreniaPsychiatric disorders4/5872/2734/530/490/540/530/491/54
Cataract subcapsularEye disorders0/5870/2731/530/490/540/530/490/54
Retinal detachmentEye disorders0/5870/2731/530/490/540/530/490/54
Psychotic disorderPsychiatric disorders2/5871/2730/530/491/540/530/491/54
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/1881/950/140/170/220/140/170/22
Suicidal ideationPsychiatric disorders1/5871/2730/530/490/540/530/490/54
Suicide attemptPsychiatric disorders1/5871/2730/530/490/540/530/490/54
Food poisoningGastrointestinal disorders0/5871/2730/530/490/540/530/490/54
Abscess limbInfections and infestations0/5871/2730/530/490/540/530/490/54
DelusionPsychiatric disorders2/5870/2730/530/490/540/530/490/54
Most frequent other events
Most frequent other events
EventCariprazine 4.5 mg/Day (Open-label Treatment Period)Cariprazine 4.5 mg/Day (Open-label Safety Follow-up)Placebo (Double-blind Treatment Period)Cariprazine 3.0 mg/Day (Double-blind Treatment Period)Cariprazine 4.5 mg/Day (Double-blind Treatment Period)Placebo (Double-blind Safety Follow-up)Cariprazine 3.0 mg/Day (Double-blind Safety Follow-up)Cariprazine 4.5 mg/Day (Double-blind Safety Follow-up)
InsomniaPsychiatric disorders50/5870/2730/534/491/540/531/490/54
HeadacheNervous system disorders38/5870/2730/530/490/540/530/490/54
Cataract nuclearEye disorders0/5870/2732/533/491/540/530/490/54
Ovarian cystReproductive system and breast disorders0/1880/950/140/170/220/141/170/22
DiarrhoeaGastrointestinal disorders0/5870/2733/532/491/540/530/490/54

Baseline characteristics

Double-blind Safety Population included all participants who took at least 1 dose of cariprazine during and double-blind treatment period.

Age, Continuous
Age, Continuous(years)Placebo (Double-blind Treatment Period)Cariprazine 3.0 mg/Day (Double-blind Treatment Period)Cariprazine 4.5 mg/Day (Double-blind Treatment Period)Total
Mean41.7 ± 10.9440.6 ± 10.8442.7 ± 11.0841.7 ± 10.92
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (Double-blind Treatment Period)Cariprazine 3.0 mg/Day (Double-blind Treatment Period)Cariprazine 4.5 mg/Day (Double-blind Treatment Period)Total
Female14172253
Male393232103
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo (Double-blind Treatment Period)Cariprazine 3.0 mg/Day (Double-blind Treatment Period)Cariprazine 4.5 mg/Day (Double-blind Treatment Period)Total
American Indian or Alaska Native1012
Asian0022
Native Hawaiian or Other Pacific Islander0000
Black or African American343839111
White17111139
More than one race1012
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo (Double-blind Treatment Period)Cariprazine 3.0 mg/Day (Double-blind Treatment Period)Cariprazine 4.5 mg/Day (Double-blind Treatment Period)Total
Hispanic10121032
Non-Hispanic433744124
08

Study locations

97 sites
  • Pillar Clinical Research
    Bentonville, Arkansas 72712, United States
  • Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • Woodland Research Northwest, LLC
    Rogers, Arkansas 72758, United States
  • Advanced Research Center, Inc.
    Anaheim, California 92805, United States
  • CITrials - Bellflower
    Bellflower, California 90706, United States
  • Synexus Clinical Research US, Inc.
    Cerritos, California 90703, United States
  • ATP Clinical Research, Inc.
    Costa Mesa, California 92626, United States
  • California Pharmaceutical Research Institute, Inc.
    Costa Mesa, California 92626, United States
  • ProScience Research Group
    Culver City, California 90230, United States
  • Collaborative Neuroscience Research Network, LLC.
    Garden Grove, California 92845, United States
  • Behavioral Research Specialists, LLC
    Glendale, California 91206, United States
  • Omega Clinical Trials
    La Habra, California 90631, United States
  • Synergy San Diego
    Lemon Grove, California 91945, United States
  • Alliance Research
    Long Beach, California 90807, United States
  • Excell Research, Inc
    Oceanside, California 92056, United States
  • Orange County Neuropsychiatric Research Center, LLC
    Orange, California 92868, United States
  • CNRI-Los Angeles
    Pico Rivera, California 90660, United States
  • University of California San Diego
    San Diego, California 92103-8229, United States
  • Schuster Medical Research Institute
    Sherman Oaks, California 91423, United States
  • Collaborative Neuroscience Research, LLC
    Torrance, California 90502, United States
  • Wilks & Safirstein MD PA D/B/A MD Clinical
    Hallandale Beach, Florida 33009, United States
  • Southern Winds Hospital
    Hialeah, Florida 33012, United States
  • Research Centers of America
    Hollywood, Florida 33024, United States
  • Synexus Clinical Research, Inc
    Atlanta, Georgia 30328, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • iResearch Atlanta LLC
    Decatur, Georgia 30030, United States
  • Atlanta Behavioral Research, LLC
    Dunwoody, Georgia 30338, United States
  • AMITA Health Alexian Brothers Center for Psychiatric Research
    Hoffman Estates, Illinois 60169, United States
  • Louisiana Clinical Research
    Shreveport, Louisiana 71101, United States
  • CBH Health LLC
    Gaithersburg, Maryland 20877, United States
  • Altea Research
    Las Vegas, Nevada 85012, United States
  • Alea Research Institute
    Las Vegas, Nevada 89102, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Neurobehavioral Research, Inc.
    Cedarhurst, New York 11516, United States
  • New Hope Clinical Research
    Charlotte, North Carolina 28211, United States
  • Clinical Inquest Center Ltd.
    Beavercreek, Ohio 45431, United States
  • OSY Psychiatry Department
    Columbus, Ohio 43210, United States
  • Professional Psychiatric Services
    Mason, Ohio 45069, United States
  • Sooner Clinical Research
    Oklahoma City, Oklahoma 23112, United States
  • Community Clinical Research, Inc.
    Austin, Texas 78754, United States
  • Pillar Clinical Research
    Richardson, Texas 75042, United States
  • Pillar Healthcare
    Richardson, Texas 75080, United States
  • Mental Health Centre - Prof.Dr.Ivan Temkov-Burgas
    Burgas, 8000, Bulgaria
  • State Psychiatry Hospital
    Kardzhali, 6600, Bulgaria
  • MHAT Dr. Hristo Stambolski" EOOD; Department of Psychiatry
    Kazanlak, 6100, Bulgaria
  • State Psyciiatric Hospital - Lovech
    Lovech, 5500, Bulgaria
  • UMHAT Dr. Georgi Stranski, EAD
    Pleven, 5800, Bulgaria
  • Mental health Centre-Ruse EOOD
    Ruse, 7003, Bulgaria
  • MHAT-Targovishte, AD
    Targovishte, 7700, Bulgaria
  • DCC Mladost M - Varna, OOD
    Varna, 9000, Bulgaria
  • Mental Health Center - Veliko Tarnovo EOOD, Veliko Tarnovo
    Veliko Tarnovo, 5000, Bulgaria
  • Mental Health Center - Vratsa EOOD, Vratsa
    Vratsa, 3000, Bulgaria
  • Inje University Busan Paik Hospital
    Busan, 47392, Korea, Republic of
  • Inje University Heaundae Paik Hospital
    Busan, 48108, Korea, Republic of
  • Chonnam National University Hospital
    Gwangju, 61469, Korea, Republic of
  • Gachon University Gil Medical Center
    Incheon, 405-760, Korea, Republic of
  • Jeju National University Hospital
    Jeju, 63241, Korea, Republic of
  • University Kuala Lumpur
    Ipoh, 30450, Malaysia
  • University Malaya Medical Center
    Kuala Lumpur, 59100, Malaysia
  • Hospital Sentosa
    Kuching, 93250, Malaysia
  • Szpital Uniwersytecki Nr.1 im. Dr. A. Jurasza, Klinika Psychiatrii
    Bydgoszcz, 85-094, Poland
  • Samodzielny Publiczny Zespół Opieki Zdrowotnej
    Chełmno, 86-200, Poland
  • Centrum Badan Klinicznych PI-House
    Gdansk, 80-546, Poland
  • Specjalistyczna Praktyka lekarska
    Lublin, 20-589, Poland
  • Indywidualna Specjalistyczna Praktyka
    Poznan, 60744, Poland
  • INSPIRA Clinical Research
    San Juan, 918, Puerto Rico
  • Spitalul de Psihiatrie si Neurologie Brasov
    Brasov, 500079, Romania
  • Armys Clinical Emergency Central Hospital Prof Dr Carol Davila
    Bucharest, 60011, Romania
  • Spitalul de Psihiatrie TITAN "Dr. Constantin Gorgoș", Bulevardul Nicolae Grigorescu, Nr. 41
    București, 30447, Romania
  • CETTT SF Stelian Hospital
    București, 60222, Romania
  • Spital Clinic Judetean Tg. Mures
    Targu Mures, 540142, Romania
  • Clinical Center of Serbia
    Belgrade, 11000, Serbia
  • Clinical Hospital Center Dr. Dragisa Misovic-Dedinje
    Belgrade, 11000, Serbia
  • Institute of Mental Health
    Belgrade, 11000, Serbia
  • Special Hospital for Psychiatric Diseases "Kovin"
    Kovin, 26220, Serbia
  • Clinical Centre Kragujevac
    Kragujevac, 34000, Serbia
  • Clinical Centre Kragujevac
    Kragujevac, 3400, Serbia
  • Specialized Hospital for Neuropsychiatric Diseases Sveti Vracevi
    Novi Knezevac, 23330, Serbia
  • Clinic for Psychiatry, Clinical Centre of Vojvodina
    Novi Sad, 21000, Serbia
  • Taipei Tzu Chi Hospital
    New Taipei City, 23142, Taiwan
  • National Cheng Kung University Hospital
    Tainan City, 70428, Taiwan
  • Department of Psychiatry, Taipei Veterans General Hospital, Taiwan
    Taipei City, 112, Taiwan
  • Suan prung Psychiatric Hospital
    Mueang Nonthaburi, 50100, Thailand
  • Regional Psychonevrological Hospital #3
    Ivano-Frankivsk, 76014, Ukraine
  • Kharkiv regional clinical psychiatric hospital #3
    Kharkiv, 31068, Ukraine
  • Institute of Neurology, Psychiatry and Narcology of the NAMS of Ukraine
    Kharkiv, 61068, Ukraine
  • SI Institute of Neurology, Psychiatry and Narcology of NAMSU
    Kharkiv, 61068, Ukraine
  • Kyiv Railway Clinical Hospital #2 of Branch "Health Center" of the Public Joint Stock Company "Ukrainian Railway"v
    Kyiv, 03049, Ukraine
  • Kyiv Regional Medical Incorporation "Psychiatry"
    Kyiv, 04080, Ukraine
  • Geikivka multidisciplinary hospital for psychiatric care
    Kyiv, 53054, Ukraine
  • KNP of Lviv Regional Council "Lviv Regional Clinical Psychiatric Hospital"
    Lviv, 79021, Ukraine
  • Odessa Regional Medical Centre of Mental Health
    Odesa, 65006, Ukraine
  • Odesa Regional Psychiatric Hospital No.2 of the ORC
    Odesa, 67513, Ukraine
  • Kherson Regional Psychiatric Institution for Psychiatric Care
    Petrivka, 73488, Ukraine
  • Cherkasy regional psychiatric hospital of the CRC
    Smila, 20704, Ukraine
  • CI O.I. Yuschenko VRPsH Depts No.14 and No.15 M.I. Pyrogov VNMU
    Vinnytsia, 21005, Ukraine
  • VNMU
    Vinnytsia, 21005, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing, please refer to the link below.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Feb 2021, 30 months.

Results were first posted in Mar 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2018
First posted
Jul 20, 2018
StartActual
Jul 30, 2018
Primary completionActual
Feb 11, 2021
CompletionActual
Feb 11, 2021
Results first posted
Mar 8, 2022
Last update
Apr 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03593213
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 20, 2018
Start date
Jul 30, 2018
Primary completion
Feb 11, 2021
Completion
Feb 11, 2021
Results posted
Mar 8, 2022
Last update
Apr 11, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion